Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ROIV stock price vs GDYN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GDYN's multiple
Needs GDYN P/S.
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · GDYN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ROIVANT SCIENCES LTD. · implied price per share
Bear
$4.51
Base
$5.30
Bull
$6.10
Grid Dynamics Holdings, Inc. · implied price per share
Bear
$5.27
Base
$6.20
Bull
$7.13
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.10x
0.06x
Net debt / EBITDA
Leverage against operating earnings
32.78x
-7.60x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$342.06M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
COGNIZANT TECHNOLOGY SOLUTIONS CORP
ROIV vs CTSH
Accenture plc
ROIV vs ACN
Globant S.A.
ROIV vs GLOB
ExlService Holdings, Inc.
ROIV vs EXLS
Rackspace Technology, Inc.
ROIV vs RXT
$442.59M
$33.72M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ROIV can reverse its steep revenue decline and materially improve margins from deeply negative levels, then the stock may warrant patience; otherwise, the relative valuation case favors avoiding or underweighting ROIV because its current price is far above GDYN on every key multiple despite much weaker fundamentals.
ROIV trades at a dramatic premium to GDYN, with a P/S of 3059.1x versus GDYN's 1.2x and EV/Revenue of 2593.1x versus 0.5x. The implied price from GDYN P/S framework is $0.01 versus the current $35.13, signaling an extreme disconnect from GDYN set and the stated valuation range.
Supporting Metrics
